特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
391378

セファロスポリン剤の世界市場 - 世代、投与経路、薬物、地理別の成長率、動向および予測

Cephalosporin Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 112 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.45円
セファロスポリン剤の世界市場 - 世代、投与経路、薬物、地理別の成長率、動向および予測
出版日: 2019年04月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 112 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のセファロスポリン剤市場は、2018年から2023年の予測期間中に約3.5%のCAGRで成長する見通しです。セファロスポリン剤は、殺菌性ベータラクタム抗生物質のクラスに属し、細菌の増殖を防ぐために細胞壁合成を阻害することによって作用します。人口の増加、経済成長、医療費、感染症の流行などにより、予測期間中はアジア太平洋地域が市場で優勢となることが予想されています。

当レポートでは、世界のセファロスポリン剤市場を調査し、全体的な市場動向、製品・地域別の詳細動向、市場成長への影響要因の分析、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ポーターのファイブフォース分析
    • サプライヤーの交渉力
    • 消費者の交渉力
    • 新規参入の脅威
    • 代替製品とサービスの脅威
    • 業界内での競争

第6章 成長要因、阻害要因、機会と挑戦分析(DROC)

  • 市場の成長要因
    • 様々な適応症における抗菌薬の需要の高まり
    • 企業の連携による研究開発活動の活性化
    • 感染症の流行
    • 併用療法の使用の増加
  • 市場の阻害要因
    • 厳格な規制ガイドライン
    • 弱いパイプライン分子
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 世代別
    • 初代
    • 第2世代
    • 第3世代
    • 第4世代
    • 第5世代
  • 投与経路別
    • 経口
    • 注射剤
  • 薬物の種類別
    • ブランド
    • ジェネリック
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • M&A分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業

  • Abbott
  • Astellas Pharma Inc.
  • Baxter International
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline PLC
  • Lupin Pharmaceuticals
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Teva Pharmaceuticals など

第10章 市場の将来展望

目次
Product Code: 52448

Market Overview

  • The major factors for the growth of the cephalosporin drugs market include the rising demand for anti-microbial in various indications, rising prevalence of infectious diseases, and increasing use of combination therapies.
  • Most of the small companies out-license the products after taking them through the early clinical development phase. These agreements usually include one-time payment for obtaining the rights, in addition to the milestone payments on completing designated developmental phase and royalties on sales. There are over 50 cephalosporin drugs that have been approved in the past five decades, and almost half of them are for the antibacterial activity. However, new cephalosporins (classified as the fifth-generation), which are used for the treatment of serious gram-negative bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA), were recently approved.
  • Manufacturers are involved in the development of new drugs to fight against anti-microbial resistance. The complexity and diversity of resistance mechanisms have defined the need for new and improved B-lactam antibiotics. Additionally, the companies are involved in the strategic development of new products, for example, in 2017, Shionogi & Co. Ltd collaborated with the F. Hoffmann-La Roche Ltd for the development and commercialization of baloxavir marboxi.
  • Thus, owing to the all above-mentioned factors the cephalosporin drugs market is expected to witness high growth over the forecast period.

Scope of the Report

As per the scope of this report, cephalosporins are part of the beta-lactams group and work by interfering with the synthesis of the bacterial cell wall. Some may be given orally, but most are given by injection. They are typically the second choice antibiotic, their main uses are in pneumonia, septicemia, meningitis, sinusitis, and UTIs treatment. Despite their second-line usage, cephalosporins have a broader spectrum of activity and are more potent than penicillin.

Key Market Trends

The Fifth-generation Segment is Expected to Account for the Largest Market Share During the Forecast Period

The fifth-generation cephalosporins were developed in the lab to specifically target resistant strains of bacteria. In particular, ceftobiprole is effective against methicillin-resistant staphylococcus aureus (MRSA). These agents are sometimes referred to as the advanced generation, rather than fifth-generation cephalosporins. Cephalosporins exhibit side effects similar to penicillin, and drug-allergy and hypersensitivity. Cephalosporins, in general, have been associated with little hepatotoxicity and rare instances of drug-induced liver injury. The fifth-generation cephalosporins include Ceftobiprole, Ceftaroline, and Ceftolozane. Ceftobiprole has powerful antipseudomonal characteristics and appears to be less susceptible to the development of resistance. Ceftaroline has also been described as the "fifth-generation" cephalosporin, but does not have the antipseudomonal or VRE coverage of ceftobiprole. The market for Ceftolozane is growing at a good pace, as it has opened gates for an alternative for the treatment of complicated intra-abdominal infections (CIAI) and complicated urinary tract infections (CUTI). Furthermore, Ceftolozane is combined with the B-lactamase inhibitor tazobactam, as multi-drug resistant bacterial infections generally exhibit resistance to all B-lactam antibiotics, unless this enzyme is inhibited. Hence, the increase in the use of combination therapies is expected to drive the market during the forecast period.

Asia-Pacific is Expected to be the Fastest Growing Segment in the Global Market

Asia-Pacific is expected to dominate this market, due to the high prevalence of infectious diseases, increasing healthcare expenditure, and a large population base. Furthermore, the demand for better healthcare infrastructure and government initiatives is expected to help the growth of the market in this region. As per the statistics published by the World Health Organization (WHO) TB statistics for India for 2016, an estimated incidence of tuberculosis (TB) is 2.79 million cases in India. Thus, rising cases of various infections are expected to boost the overall growth of the market. Asia-Pacific is followed by Europe, due to its large base of geriatric population and rising prevalence of infectious diseases in several countries of the region.

Competitive Landscape

The market studied is fragmented, owing to the presence of many small and large market players. Some of the market players are Astellas Pharma Inc., Baxter International, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Lupin Pharmaceuticals, Macleods Pharmaceuticals Ltd., Mankind Pharma, Merck & Co. Inc., Pfizer Inc., and Teva Pharmaceuticals.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Demand for Anti-microbials in Various Indications
    • 4.2.2 Rising Prevalence of Infectious Diseases
    • 4.2.3 Increasing Use of Combination Therapies
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Guidelines
    • 4.3.2 Weak Pipeline Molecules
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Generation
    • 5.1.1 First-generation
    • 5.1.2 Second-generation
    • 5.1.3 Third-generation
    • 5.1.4 Fourth-generation
    • 5.1.5 Fifth-generation
  • 5.2 By Prescription Type
    • 5.2.1 Prescription Drugs
    • 5.2.2 OTC Drugs
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Aristo Pharmaceuticals Ltd
    • 6.1.2 Baxter International
    • 6.1.3 F. Hoffmann-La Roche AG
    • 6.1.4 GlaxoSmithKline PLC
    • 6.1.5 Lupin Pharmaceuticals Inc.
    • 6.1.6 Macleods Pharmaceuticals Ltd
    • 6.1.7 Mankind Pharma
    • 6.1.8 Merck & Co. Inc.
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Teva Pharmaceutical Industries Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.